Trial Profile
A Phase I/II Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 12 Dec 2023
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Vorinostat (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms QUAD
- 01 Dec 2023 Planned End Date changed from 1 Nov 2023 to 1 Nov 2024.
- 01 Dec 2023 Planned primary completion date changed from 1 Nov 2023 to 1 Nov 2024.
- 23 Dec 2022 Planned End Date changed from 1 Nov 2022 to 1 Nov 2023.